Bevacizumab: all 1,786 studies that test it
Page 13 of 18. Open to participants first (285), then studies with results posted, then the rest; newest registration first within each.
- Efficacy and Safety of Bevacizumab Plus Sorafenib for the Third-line Treatment in Metastatic Renal Cancer PatientsStatus unknownNCT02330783Phase 2
- Open-label Study in Patients With Metastatic NSLC Treated With Cisplatin, Gemcitabine and BevacizumabCompletedNCT02316327Phase 4
- Bevacizumab Therapy for Brain Arteriovenous MalformationCompletedNCT02314377Phase 1
- Prospective, Randomized Clinical Trial Comparing Macular Photocoagulation With or Without Intravitreal Bevacizumab or Triamcinolone for the Treatment of Diabetic Macular EdemaCompletedNCT02310295Not applicable
- Intravitreous Bevacizumab and Standard Metabolic Control for Diabetic Macular Edema - A Contrast Sensitivity StudyCompletedNCT02308644Phase 3
- Activity Study of Bevacizumab With Temozolomide ± Irinotecan for Neuroblastoma in ChildrenCompletedNCT02308527Phase 2
- Comparison of Pharmacokinetics of and Effect on Systemic VEGF Levels in Age Related Macular Degeneration PatientsStatus unknownNCT02296567Phase 2/3
- Maintenance Bevacizumab Only or Bevacizumab Plus Metronomic Chemotherapy in Advanced Colorectal CancerCompletedNCT02271464Phase 2
- Efficacy and Safety of TC+AVASTIN Versus TC in Patients With Metastatic Nasopharyngeal CarcinomaStatus unknownNCT02250599Phase 2
- Intrapleural Bevacizumab After Pleural Drainage in the Context of Breast CancerTerminatedNCT02250118Phase 1
- Patient Preference for Everolimus in Combination With Exemestane or Capecitabine in Combination With BevacizumabCompletedNCT02248571Phase 4
- A Multicenter, Clinical Study of FOLFOXIRI With Bevacizumab As First-line Therapy in Patients With mCRCCompletedNCT02246049Phase 2
- Bevacizumab-containing Regimen for Metastatic Colorectal Cancer Failed to Cytotoxic TreatmentStatus unknownNCT02226289Phase 2
- Dose Escalation of Cisplatin Hyperthermic Intraperitoneal Chemotherapy After Surgery in Patients With Unresectable Stage IIIC Ovarian, Tube or Peritoneal Primary AdenocarcinomaCompletedNCT02217956Phase 1
- Nivolumab With or Without Bevacizumab or Ipilimumab Before Surgery in Treating Patients With Metastatic Kidney Cancer That Can Be Removed by SurgeryActive, not recruitingNCT02210117Early Phase 1
- The Safety and Efficacy of Pemetrexed Rechallenge With BevacizumabTerminatedNCT02200354Phase 2
- dMR During First Line Treatment of Non Squamous Lung Cancer: Time Course and Prognostic and Predictive Impact.Status unknownNCT02195336Not applicable
- CRLX101(NLG207) in Combination With Bevacizumab for Metastatic Renal Cell Carcinoma (mRCC) Versus Standard of Care (SOC)CompletedNCT02187302Phase 2
- Bevacizumab, Etoposide and Cisplatin Followed by Whole Brain Radiotherapy in Breast Cancer With Brain MetastasesStatus unknownNCT02185352Phase 2
- Docetaxel Plus Bevacizumab for Elderly Patients With Stage IV NSCLCTerminatedNCT02179567Phase 2
- Safety and Efficacy Study of Eribulin in Combination With Bevacizumab for Second-line Treatment HER2- MBC PatientsStatus unknownNCT02175446Phase 2
- Treatment Strategies in Colorectal Cancer Patients with Initially Unresectable Liver-only MetastasesCompletedNCT02162563Phase 3
- Therapeutic Strategies in Patients With Non-squamous Non-small Cell Lung Cancer With Brain MetastasesTerminatedNCT02162537Phase 3
- Efficacy and Safety Study of Bevacizumab Plus Chemotherapy in EGFR-TKI Resistant Non-Squamous Non-Small Cell Lung CancerStatus unknownNCT02139579Phase 2
- Dose-Escalation Study of Intraperitoneal (IP) Cisplatin, IV/IP Paclitaxel, IV Bevacizumab, and Oral Olaparib for Newly Diagnosed Ovarian, Primary Peritoneal, and Fallopian Tube CancerCompletedNCT02121990Phase 1
- Efficacy of a Bevacizumab Nasal Spray as a Treatment for Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT)TerminatedNCT02106520Phase 2/3
- Bevacizumab and Peripheral Retinal Changes on Wide Field Angiography in Diabetic Macular EdemaCompletedNCT02096874Phase 4
- PERIOPERATIVE TREATMENT WITH COI-B (CAPECITABINE, OXALIPLATIN, IRINOTECAN AND BEVACIZUMAB) OF HIGH RISK OR BORDERLINE RESECTABLE COLORECTAL CANCER LIVER METASTASESCompletedNCT02086656Phase 2
- Angiogenic Factor Expression During Fractionated IrradiationStatus unknownNCT02072720Early Phase 1
- Combo of Abraxane, TMZ, Bevacizumab in Metastatic Melanoma With Brain MetastasesWithdrawnNCT02065466Phase 1/2
- Efficacy and Safety of Bevacizumab Versus Pulvis Talci in Malignant Pleural EffusionStatus unknownNCT02054078Phase 2
- Intrapleural Bevacizumab Injection for Malignant Effusion in Lung CancerCompletedNCT02054052Phase 2
- Neoadjuvant Bev Plus DOF vs DOF in LAGC and Its Association With Circulating Tumor CellCompletedNCT02048540Phase 1/2
- Safety & Efficacy Study of TPI 287 + Avastin in Adults With Glioblastoma That Progressed Following Prior Avastin TherapyTerminatedNCT02047214Phase 2
- Safety and Efficacy Study of BCD-021 Compared to Lucentis® in Patients With Neovascular Wet Age-related Macular DegenerationWithdrawnNCT02036723Phase 3
- A Pharmacokinetic Study Comparing PF-06439535 And Bevacizumab In Healthy Male Volunteers (REFLECTIONS B739-01)CompletedNCT02031991Phase 1
- Bevacizumab Combined With Carboplatin Plus Paclitaxel Chemotherapy to Treat Metastatic Mucosal MelanomaStatus unknownNCT02023710Phase 2
- Postoperative Adjuvant Chemotherapy With Bevacizumab and Maintenance Bevacizumab After Neoadjuvant Chemotherapy for Ovarian CancerCompletedNCT02022917Phase 2
- Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological CancersCompletedNCT02020707Phase 1
- Intravitreal Bevacizumab for the Treatment of CNV in VKH Disease - A Prospective StudyCompletedNCT02015351Not applicable
- Intrapleural Administration of Bevacizumab Versus Endostar for Pleural Effusions in NSCLCStatus unknownNCT02005120Phase 2
- Evaluation of FDOPA-PET/MRI in Pediatric Patients With CNS TumorsCompletedNCT01999270Phase 1
- A Phase III Study of 2nd-line XELIRI ± Bevacizumab vs. FOLFIRI ± Bevacizumab in mCRCCompletedNCT01996306Phase 3
- A Study to Evaluate the Safety and Pharmacology of DNIB0600A in Participants With Platinum-Sensitive Ovarian Cancer or Non-Squamous Non-small Cell Lung CancerCompletedNCT01995188Phase 1
- Chemotherapy Plus Bevacizumab in Elderly Non-small Cell Lung Cancer PatientsStatus unknownNCT01980472Phase 2
- Pre-Operative Intravitreal Bevacizumab for Tractional Retinal Detachment Secondary to Proliferative Diabetic RetinopathyCompletedNCT01976923Phase 3
- Avastin in Combination With Chemotherapy for RAS Mutant Unresectable Colorectal Liver-limited MetastasesCompletedNCT01972490Phase 4
- Salvage Chemotherapy for Poor Prognosis Germ Cell TumorsStatus unknownNCT01966913Phase 1/2
- Preoperative Chemotherapy With Bevacizumab For Potentially Resectable Gastric Cancer With Liver MetastasisStatus unknownNCT01962376Phase 4
- Phase 1/2 CTO + Bevacizumab for Recurrent Glioma Post-Bevacizumab FailureTerminatedNCT01954030Phase 1
- Pemetrexed/Platinum With or Without Bevacizumab in Brain Metastases From Patients With EGFR/ALK Negative Non-Squamous Non-small Cell Lung CancerCompletedNCT01951482Phase 3
- 8 Continuous vs 8 Intermittent Cycles in First and Second Line in HER2/Neu Neg Metastatic Breast CancerCompletedNCT01935492Phase 3
- An Interventional Study of Avastin (Bevacizumab) in Patients With Advanced/Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal CancerCompletedNCT01932125Phase 4
- Avastin+ GemAOD As First-Line Treatment in NK/T Cell LymphomaStatus unknownNCT01921790Phase 2
- A Phase I Study of TAS-102 in Patients With Advanced Gastrointestinal Tumors.CompletedNCT01916447Phase 1
- A Phase I Study of High-dose L-methylfolate in Combination With Temozolomide and Bevacizumab in Recurrent High Grade GliomaCompletedNCT01891747Phase 1
- Efficacy and Safety of Bevacizumab in the Neodjuvant Treatment of Inflammatory Breast CancerStatus unknownNCT01880385Phase 1
- Risk-Adapted Focal Proton Beam Radiation and/or Surgery in Patients With Low, Intermediate and High Risk Rhabdomyosarcoma Receiving Standard or Intensified ChemotherapyActive, not recruitingNCT01871766Phase 2
- A Comparison of Continuous Bevacizumab (Avastin) Treatment or Placebo in Addition to Lomustine Followed by Standard of Care After Disease Progression in Participants With GlioblastomaCompletedNCT01860638Phase 2
- First-line Irinotecan, Lederfolin and 5FU (FOLFIRI) and Bevacizumab in Patients With Advanced Colorectal CancerCompletedNCT01853813Phase 2
- Phase I Trial of Intraperitoneal Bevacizumab in Refractory Malignant AscitesStatus unknownNCT01852409Phase 1
- Neoadjuvant Therapy in Advanced Ovarian Cancer With AvastinTerminatedNCT01847677Phase 2
- Clinical Study in Treatment of Malignant Ascites of Ovarian Cancer With Intraperitoneal Injection Bevacizumab Combined With Intraperitoneal Hyperthermic Perfusion ChemotherapyStatus unknownNCT01838538Phase 2
- Evaluation of Optimal Treatment With Bevacizumab in Patients With Platinum-sensitive Recurrent Ovarian CancerCompletedNCT01837251Phase 3
- Achievement of Improved Survival by Molecular Targeted Chemotherapy and Liver Resection for Not Optimally Resectable Colorectal Liver MetastasesCompletedNCT01836653Phase 2
- Exploratory Study in Achievement of Improved Survival by Molecular Targeted Chemotherapy and Liver Resection for Not Optimally Resectable Colorectal Liver MetastasesCompletedNCT01834014Not applicable
- Combined Intravitreal Fasudil and Bevacizumab for Diabetic Macular EdemaCompletedNCT01823081Phase 3
- Preoporative Bevacizumab, Radiation Therapy, and XELOX Chemotherapy for Locally Advanced Nonmetastatic Rectal CancerStatus unknownNCT01818973Phase 2
- Bevacizumab Beyond Progression in Platinum Sensitive Ovarian CancerStatus unknownNCT01802749Phase 3
- Cetuximab/FOLFIRI With or Without Oxaliplatin and FOLFOXIRI With or Without Bevacizumab in Neoadjuvant Treatment of Non-resectable Colorectal Liver MetastasesStatus unknownNCT01802645Phase 2
- Trial of Switching Between Intravitreal Bevacizumab (Avastin®)& Intravitreal Dexamethasone (Ozurdex™) for Persistent Diabetic Macular OedemaCompletedNCT01787669Phase 2
- Ph II Cilengitide Plus Bevacizumab for Recurrent Glioblastoma (GBM)WithdrawnNCT01782976Phase 2
- PRevention of Macular EDema After Cataract SurgeryCompletedNCT01774474Phase 3
- Efficacy and Safety of Bevacizumab (Avastin®) Combined to Weekly Paclitaxel Followed by Bevacizumab (Avastin®) Alone in Patients With Relapsed Ovarian Sex-cord Stromal Tumours (ALIENOR)CompletedNCT01770301Phase 2
- Carboplatin-Paclitaxel ± Bevacizumab in Advanced (Stage III-IV) or Recurrent Endometrial CancerStatus unknownNCT01770171Phase 2
- Dexamethasone-implant for the Treatment of RVOCompletedNCT01767545Phase 4
- Paclitaxel-bevacizumab in Advanced Lung CancerCompletedNCT01763671Phase 3
- Bevacizumab Therapy Untreated Unresectable Liver Metastases From Colorectal CancerStatus unknownNCT01763450Phase 2
- Chemoradiotherapy for Patients With Oligometastatic Colorectal CancerTerminatedNCT01759238Phase 2
- Tivantinib and Bevacizumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by SurgeryCompletedNCT01749384Phase 1
- Bevacizumab/Doxorubicin/Radiation for SarcomaActive, not recruitingNCT01746238Phase 1
- Subconjunctival Bevacizumab and Recurrent PterygiumCompletedNCT01744756Phase 2/3
- A Study of Bevacizumab (Avastin) in Neoadjuvant Therapy in Participants With International Federation of Gynecology and Obstetrics (FIGO) Stage IIIC/IV Ovarian, Tubal, or Peritoneal Cancer, Initially UnresectableCompletedNCT01739218Phase 2
- Role of Sub-Conjunctival Bevacizumab in Post Pterygium Excision ManagementCompletedNCT01736449Phase 4
- Bevacizumab and Trabectedin +/- Carboplatin in Advanced Ovarian CancerCompletedNCT01735071Phase 2
- Intravitreal Bevacizumab for Proliferative Diabetic RetinopathyCompletedNCT01724385Phase 4
- A Biomarker Study in Patients With HER2-negative Metastatic Breast Cancer Treated With Bevacizumab and PaclitaxelCompletedNCT01722968Phase 2
- Study of Clinical and Biological Prognostic Factors in Patients With Ovarian Cancer Receiving Carboplatin +Paclitaxel With BevacizumabStatus unknownNCT01706120Phase 4
- Bevacizumab vs Dacarbazine in Metastatic MelanomaTerminatedNCT01705392Phase 2
- Re-introduction of Pemetrexed and Cisplatin With Prolonged Angiogenic Blocking by Bevacizumab in Advanced Lung Cancer.CompletedNCT01705184Phase 2
- Study of Everolimus, Pemetrexed, Carboplatin, and Bevacizumab to Treat Stage IV Lung CancerCompletedNCT01700400Phase 1
- Bevacizumab for Primary Pterygium TreatmentCompletedNCT01686529Phase 1
- Pazopanib Hydrochloride and Bevacizumab in Treating Patients With Previously Untreated Metastatic Kidney CancerActive, not recruitingNCT01684397Phase 1/2
- Study of Bevacizumab Plus Chemotherapy in Patients With Metastatic Colorectal CancerStatus unknownNCT01679327Phase 2
- Intra-arterial Hepatic Bevacizumab and Systemic ChemotherapyCompletedNCT01677884Phase 2
- TS Stratified Chemotherapy and VEGF Inhibition in Non-Squamous Non-Small Cell Lung Cancer - Stage IVWithdrawnNCT01674738Phase 2
- Bevacizumab Plus Modified FOLFOX6 Regimen as the Salvage Treatment in Metastatic Breast Cancer (MBC) PatientsCompletedNCT01658033Phase 2
- "Phase II Study of PET Guided Neoadjuvant Chemotherapy (NAC) and Oncotype Guided Hormonal Therapy of Breast Cancer"Status unknownNCT01641406Phase 2
- Influence of BRAF and PIK3K Status on the Efficacy of 5-Fluorouracil/Leucovorin/Oxaliplatin (FOLFIRI) Plus Bevacizumab or Cetuximab in Patients With RAS Wild-type Metastatic Colorectal Carcinoma and < 3 Circulating Tumor Cells (CTC)CompletedNCT01640444Phase 2
- Study of 5-Fluorouracil/Leucovorin/Oxaliplatin (FOLFOX) + Bevacizumab Versus 5-Fluorouracil/Leucovorin/Oxaliplatin/Irinotecan (FOLFOXIRI) + Bevacizumab as First Line Treatment of Patients With Metastatic Colorectal Cancer Not Previously Treated and With Three or More Circulating Tumoral CellsCompletedNCT01640405Phase 3